Click for full image >>
is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.
TG Therapeutics, Inc. Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
TG Therapeutics Announces Orphan Drug Designation for TGR-1202 for Treatment of Chronic Lymphocytic Leukemia
2 Gansevoort Street, 9th Floor, New York NY 10014 - P:212.554.4484 - Email Us
Web Site Development by Tidal Media Group